Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis

Trial Profile

Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Methotrexate (Primary) ; Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 09 Nov 2015 Results from this trial were presented at the Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy Strategies session to be held during the 2015 Annual Meeting of the American College of Rheumatology, according to an Antares Pharma media release.
    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Profile updated with data presented in an Antares Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top